2024 |
SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease |
Articolo in rivista |
Vai |
2024 |
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease |
Articolo in rivista |
Vai |
2024 |
Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease |
Articolo in rivista |
Vai |
2024 |
ANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization |
Articolo in rivista |
Vai |
2024 |
Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis |
Articolo in rivista |
Vai |
2024 |
Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD |
Articolo in rivista |
Vai |
2024 |
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) |
Articolo in rivista |
Vai |
2024 |
Corrigendum to “SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease” [J Hepatol 80 (2024) 10-19, (S0168827823051474), (10.1016/j.jhep.2023.09.020)] |
Nota o commento |
Vai |
2024 |
Correction to: Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women (Nature Medicine, (2023), 29, 10, (2643-2655), 10.1038/s41591-023-02553-8) |
Nota o commento |
Vai |
2024 |
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease |
Articolo in rivista |
Vai |
2024 |
Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria |
Articolo in rivista |
Vai |
2024 |
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease |
Articolo in rivista |
Vai |
2024 |
Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome |
Articolo in rivista |
Vai |
2024 |
Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and Comprehensibility |
Articolo in rivista |
Vai |
2024 |
Performance of ultrasound-guided attenuation parameter and 2D shear wave elastography in patients with metabolic dysfunction-associated steatotic liver disease |
Articolo in rivista |
Vai |
2024 |
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies |
Articolo in rivista |
Vai |
2024 |
Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease? |
Review essay (rassegna critica) |
Vai |
2024 |
The PD-1/PD-L1 Axis in the Biology of MASLD |
Review essay (rassegna critica) |
Vai |
2023 |
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study |
Articolo in rivista |
Vai |
2023 |
Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease |
Articolo in rivista |
Vai |
2023 |
MAFLD: a multisystem disease |
Recensione in rivista |
Vai |
2023 |
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis |
Articolo in rivista |
Vai |
2023 |
Point-of-Care Noninvasive Prediction of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease |
Articolo in rivista |
Vai |
2023 |
Inflammation and autonomic balance in cirrhosis: Association between sympathetic nervous system and osteopontin, interleukin-22, interleukin-6 and interleukin-1Ra concentrations according to portal hypertension and disease severity |
Articolo in rivista |
Vai |
2023 |
Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease |
Articolo in rivista |
Vai |
2023 |
Heart rate variability is associated with disease severity and portal hypertension in cirrhosis |
Articolo in rivista |
Vai |
2023 |
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women |
Articolo in rivista |
Vai |
2023 |
Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease |
Articolo in rivista |
Vai |
2023 |
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes |
Articolo in rivista |
Vai |
2022 |
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices |
Articolo in rivista |
Vai |
2022 |
A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease |
Articolo in rivista |
Vai |
2022 |
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD |
Articolo in rivista |
Vai |
2022 |
Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis |
Articolo in rivista |
Vai |
2022 |
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach? |
Articolo in rivista |
Vai |
2022 |
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease |
Articolo in rivista |
Vai |
2022 |
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis |
Articolo in rivista |
Vai |
2021 |
Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C |
Articolo in rivista |
Vai |
2021 |
THE ROLE OF TRANSIENT ELASTOGRAPHY IN NAFLD |
Capitolo o Saggio |
Vai |
2021 |
Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population |
Articolo in rivista |
Vai |
2021 |
Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease |
Articolo in rivista |
Vai |
2021 |
Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease |
Articolo in rivista |
Vai |
2021 |
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease |
Articolo in rivista |
Vai |
2021 |
NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease |
Articolo in rivista |
Vai |
2020 |
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease |
Articolo in rivista |
Vai |
2020 |
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease |
Articolo in rivista |
Vai |
2020 |
Biochemical biomarkers of NAFLD/NASH |
Capitolo o Saggio |
Vai |
2020 |
IMPACT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON CARDIOVASCULAR RISK IN A GENERAL POPULATION |
Abstract in atti di convegno pubblicato in rivista |
Vai |
2020 |
PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD |
Articolo in rivista |
Vai |
2020 |
Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD |
Articolo in rivista |
Vai |
2020 |
PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease |
Articolo in rivista |
Vai |
2020 |
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease |
Articolo in rivista |
Vai |
2019 |
Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis |
Articolo in rivista |
Vai |
2019 |
IMPACT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON CARDIOVASCULAR RISK IN A GENERAL POPULATION |
Abstract in atti di convegno pubblicato in rivista |
Vai |
2019 |
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives |
Articolo in rivista |
Vai |
2019 |
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives |
Articolo in rivista |
Vai |
2018 |
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? |
Articolo in rivista |
Vai |